News & Updates

Rivaroxaban slows renal decline in NVAF patients

08 Feb 2022

Compared with warfarin, rivaroxaban lowers the risk and rate of renal decline in patients with nonvalvular atrial fibrillation (NVAF), a new study reports.

Rivaroxaban slows renal decline in NVAF patients

08 Feb 2022

Long-term tolvaptan cost-effective only in CHF patients needing high-dose furosemide

07 Feb 2022

While tolvaptan does not seem to provide a clear economic benefit in all patients with chronic heart failure (CHF), its use in those who require high-dose furosemide may be cost-effective, a recent study has found.

Long-term tolvaptan cost-effective only in CHF patients needing high-dose furosemide

07 Feb 2022

Aerobic dance training maintains cognition in older people with CSVD

05 Feb 2022 by

A rater-blind randomized trial conducted by the Chinese University of Hong Kong (CUHK) in collaboration with the Hong Kong Polytechnic University and BrainNow Research Institute in Shenzhen, China, has found that regular aerobic exercise led to pulse and blood pressure (BP) reductions as well as maintenance of global cognition in older people with moderate to severe subclinical cerebral small vessel disease (CSVD).

Aerobic dance training maintains cognition in older people with CSVD

05 Feb 2022

Atrial fibrillation self-management with an app: Good to go in SG?

04 Feb 2022 by

A novel mobile application to help patients self-manage atrial fibrillation (AF) has been found useful and acceptable for Asians, according to a Singapore study.

Atrial fibrillation self-management with an app: Good to go in SG?

04 Feb 2022

Vericiguat addresses unmet needs in worsening HFrEF

04 Feb 2022

Heart failure (HF) is a complicated clinical syndrome that is inherently progressive. In HF with reduced ejection fraction (HFrEF), the left ventricular ejection fraction (LVEF) is ≤40 percent and accompanied by progressive LV dilatation and adverse cardiac remodeling. [Eur J Heart Fail 2021;23:352-380]

Vericiguat addresses unmet needs in worsening HFrEF

04 Feb 2022

Work disability more than thrice as likely after AF

03 Feb 2022

Atrial fibrillation (AF) substantially aggravates the likelihood of work disability, particularly in patients of low socioeconomic status, a recent study has found.

Work disability more than thrice as likely after AF

03 Feb 2022

Longitudinal high-sensitivity troponin T predicts mortality in CKD

03 Feb 2022

An independent association exists between longitudinally measured cardiac troponin T (cTnT) and mortality risk in older patients with stage 4 and 5 chronic kidney disease (CKD), reveals a study. This suggests that monitoring patients with cTnT may serve well in identifying those with a high death risk.

Longitudinal high-sensitivity troponin T predicts mortality in CKD

03 Feb 2022

Prehospital delay ups risk of all-cause mortality in NSTEMI

03 Feb 2022

In patients with non‒ST-segment elevation myocardial infarction (NSTEMI), prehospital delay appears to increase their risk of 3-year all-cause mortality, a study has shown.

Prehospital delay ups risk of all-cause mortality in NSTEMI

03 Feb 2022

Sacubitril/valsartan equals enalapril, valsartan alone for preventing AF in HF

31 Jan 2022

Sacubitril/valsartan performs comparably as enalapril or valsartan alone in preventing atrial fibrillation (AF) occurrence in patients with heart failure (HF), reports a recent meta-analysis.

Sacubitril/valsartan equals enalapril, valsartan alone for preventing AF in HF

31 Jan 2022

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022 by

Treatment with a single-pill combination (SPC) drug, composed of olmesartan and amlodipine, plus a separate dose of rosuvastatin led to significantly reduced systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels in patients with concomitant hypertension and dyslipidaemia, according to the LEISURE* trial.

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022

News & Updates

Filter by Specialty:

Specialty:

Rivaroxaban slows renal decline in NVAF patients

Rivaroxaban slows renal decline in NVAF patients

Long-term tolvaptan cost-effective only in CHF patients needing high-dose furosemide

Long-term tolvaptan cost-effective only in CHF patients needing high-dose furosemide

Aerobic dance training maintains cognition in older people with CSVD

Aerobic dance training maintains cognition in older people with CSVD

Atrial fibrillation self-management with an app: Good to go in SG?

Atrial fibrillation self-management with an app: Good to go in SG?

Vericiguat addresses unmet needs in worsening HFrEF

Vericiguat addresses unmet needs in worsening HFrEF

Work disability more than thrice as likely after AF

Work disability more than thrice as likely after AF

Longitudinal high-sensitivity troponin T predicts mortality in CKD

Longitudinal high-sensitivity troponin T predicts mortality in CKD

Prehospital delay ups risk of all-cause mortality in NSTEMI

Prehospital delay ups risk of all-cause mortality in NSTEMI

Sacubitril/valsartan equals enalapril, valsartan alone for preventing AF in HF

Sacubitril/valsartan equals enalapril, valsartan alone for preventing AF in HF

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia